TXN and pancreatic neoplasm: Another phase II study of PX-12 on previously treated advanced pancreatic cancer also reported no consistent decrease in SUV, Trx-1 levels, or CA 199 levels and was terminated early due to limited antitumor activity as well as low baseline Trx-1 levels [521] (NCT00177242).